Experts from The Cancer Institute at NYU Langone Medical Center presented new research findings at the American Association for Cancer Research 102nd Annual Meeting 2011 held April 2-6, 2011 in Orlando, Florida. NYU Cancer Institute researchers discussed various breakthroughs such as a novel test for early-stage asbestos-related pulmonary cancer, a promising mesothelioma treatment strategy for glioblastomas ...
NYU Cancer Institute experts present at the AACR 102nd Annual Meeting 2011
( NYU Langone Medical Mesothelioma Center / New York University School of Medicine ) Experts from the Cancer Institute at NYU Langone Medical Center presented new research findings at the American Association for Cancer Research 102nd Annual Meeting 2011 held April 2-6, 2011 in Orlando, Fla., NYU Cancer Institute researchers discussed various breakthroughs such as a novel test for early-stage asbestos ...
Polaris Enrolls First Patient In Phase 2 Clinical Trial Of ADI-PEG 20 For The Treatment Of Malignant Mesothelioma
Sun, 20 Mar 2011 02:14:10 -0700
Polaris Group announced the enrollment of the first patient in a Phase 2 clinical trial of ADI-PEG 20 (pegylated arginine deiminase), the company's novel enzyme-based treatment for malignant mesothelioma. This randomized trial, called "ADAM" (Arginine Deiminase And Mesothelioma), will evaluate the treatment efficacy of ADI-PEG 20 as a single agent compared to the best supportive care. The ...
Polaris initiates ADI-PEG 20 Phase 2 trial in patients with malignant mesothelioma
Fri, 18 Mar 2011 21:56:58 -0700
Polaris Group announced today the enrollment of the first patient in a Phase 2 clinical trial of ADI-PEG 20, the company's novel enzyme-based treatment for malignant mesothelioma
NYU Cancer Institute experts present at the AACR 102nd Annual Meeting 2011
( NYU Langone Medical Mesothelioma Center / New York University School of Medicine ) Experts from the Cancer Institute at NYU Langone Medical Center presented new research findings at the American Association for Cancer Research 102nd Annual Meeting 2011 held April 2-6, 2011 in Orlando, Fla., NYU Cancer Institute researchers discussed various breakthroughs such as a novel test for early-stage asbestos ...
Polaris Enrolls First Patient In Phase 2 Clinical Trial Of ADI-PEG 20 For The Treatment Of Malignant Mesothelioma
Sun, 20 Mar 2011 02:14:10 -0700
Polaris Group announced the enrollment of the first patient in a Phase 2 clinical trial of ADI-PEG 20 (pegylated arginine deiminase), the company's novel enzyme-based treatment for malignant mesothelioma. This randomized trial, called "ADAM" (Arginine Deiminase And Mesothelioma), will evaluate the treatment efficacy of ADI-PEG 20 as a single agent compared to the best supportive care. The ...
Polaris initiates ADI-PEG 20 Phase 2 trial in patients with malignant mesothelioma
Fri, 18 Mar 2011 21:56:58 -0700
Polaris Group announced today the enrollment of the first patient in a Phase 2 clinical trial of ADI-PEG 20, the company's novel enzyme-based treatment for malignant mesothelioma
No comments:
Post a Comment